Answers are grounded in this paper and cite their sources.
Immunocompromised individuals remain at risk of severe COVID-19. This multicentre, open-label, phase II randomised controlled trial evaluated the safety, pharmacokinetics and immunogenicity of co-administering the long-acting monoclonal antibody AZD7442 with a bivalent (Ancestral/BA.1) mRNA/LNP SARS-CoV-2 vaccine. A total of 139 immunocompromised adults received AZD7442 followed 28 days later by vaccination. AZD7442 was well tolerated, with no serious adverse events. Serum AZD7442 concentrations peaked at day 28 and remained detectable across disease cohorts at day 180. Anti-Spike antibody responses increased after AZD7442 and reached their highest levels after vaccination. Although binding antibodies against Omicron variants increased post-vaccination, neutralisation of Omicron remained limited after both AZD7442 and vaccination. Vaccination preferentially boosted antibodies targeting S2, the S1 N-terminal domain and receptor-binding domain epitopes not bound by AZD7442, and increased S2-specific memory B cells. Vaccine-induced T-cell responses were cross-reactive between ancestral and Omicron variants. Our findings support consideration of combined antibody and vaccine strategies in future therapeutic antibody development. The trial is registered with the International Standard Randomised Controlled Trial Number registry (ISRCTN53507177).
No takes yet. Share an insight, caveat, or question.
Frumento et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: